Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  HIV Infection

  Free Subscription


15.05.2017

13 AIDS
3 AIDS Res Hum Retroviruses
1 Am J Epidemiol
1 Antimicrob Agents Chemother
1 Antivir Ther
8 Clin Infect Dis
29 J Acquir Immune Defic Syndr
2 J Infect Dis
3 J Virol
2 Lancet Glob Health
4 Lancet HIV
3 Lancet Infect Dis
1 MMWR Morb Mortal Wkly Rep
1 Nat Med
2 Pediatr Infect Dis J
14 PLoS One
2 PLoS Pathog
1 Science
2 Vaccine


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AIDS

  1. KENNEDY CE, Yeh PT, Pandey S, Betran AP, et al
    Elective cesarean section for women living with HIV: a systematic review of risks and benefits.
    AIDS. 2017 May 5. doi: 10.1097/QAD.0000000000001535.
    PubMed     Text format     Abstract available

  2. MARSHALL BDL, Tate JP, McGinnis KA, Bryant KJ, et al
    Long-term alcohol use patterns and HIV disease severity.
    AIDS. 2017;31:1313-1321.
    PubMed     Text format     Abstract available

  3. FOX J, Collins S
    HIV prevention: response to pre-exposure prophylaxis failure with tenofovir disoproxil.
    AIDS. 2017;31:1343.
    PubMed     Text format    

  4. ESSER S, Streeck H
    Preexposure prophylaxis failure with tenofovir disoproxil.
    AIDS. 2017;31:1344.
    PubMed     Text format    

  5. MCMAHON JH, Chang J, Tennakoon S, Dantanarayana A, et al
    Post-treatment control in an adult with perinatally acquired HIV following cessation of antiretroviral therapy.
    AIDS. 2017;31:1344-1346.
    PubMed     Text format    

  6. GRIESBECK M, Valantin MA, Lacombe K, Samri-Hassimi A, et al
    Hepatitis C virus drives increased type I interferon-associated impairments associated with fibrosis severity in antiretroviral treatment-treated HIV-1-hepatitis C virus-coinfected individuals.
    AIDS. 2017;31:1223-1234.
    PubMed     Text format     Abstract available

  7. LECCA L, Galea J, Contreras CC, Millones AK, et al
    Challenges in tuberculosis/HIV management in a country with a concentrated HIV epidemic.
    AIDS. 2017;31:1207-1209.
    PubMed     Text format    

  8. VANPOUILLE C, Bernatchez JA, Lisco A, Arakelyan A, et al
    A common anti-CMV drug, ganciclovir, inhibits HIV-1 replication in human tissues ex vivo.
    AIDS. 2017 May 5. doi: 10.1097/QAD.0000000000001532.
    PubMed     Text format     Abstract available

  9. TOBIN SC
    WHO provides additional guidance on HIV self-testing and partner notification.
    AIDS. 2017 May 5. doi: 10.1097/QAD.0000000000001537.
    PubMed     Text format    

  10. MORENO M, Caballero E, Mateus RM, Samba F, et al
    HIV drug resistance in Africa: an emerging problem that deserves urgent attention.
    AIDS. 2017 May 5. doi: 10.1097/QAD.0000000000001536.
    PubMed     Text format    

  11. TODESCO E, Demeret S, Calin R, Roque-Afonso AM, et al
    Chronic hepatitis E in HIV/HBV coinfected patient: lack of power of sofosbuvir-ribavirin.
    AIDS. 2017;31:1346-1348.
    PubMed     Text format    

  12. CABY F
    CD4/CD8 ratio restoration in long-term treated HIV-1-infected individuals: Incidence and determinants.
    AIDS. 2017 May 5. doi: 10.1097/QAD.0000000000001533.
    PubMed     Text format     Abstract available

  13. RYOM L, Mocroft A, Kirk O, Reiss P, et al
    Predictors of estimated glomerular filtration rate progression, stabilization or improvement after chronic renal impairment in HIV-positive individuals.
    AIDS. 2017;31:1261-1270.
    PubMed     Text format     Abstract available


    AIDS Res Hum Retroviruses

  14. HONGJAISEE S, Braibant M, Barin F, Ngo-Giang-Huong N, et al
    Effect of Amino Acid Substitutions within the V3 Region of HIV-1 CRF01_AE on Interaction with CCR5-coreceptor.
    AIDS Res Hum Retroviruses. 2017 May 12. doi: 10.1089/AID.2017.0044.
    PubMed     Text format     Abstract available

  15. CENKER JJ, Stultz RD, McDonald D
    Brain microglial cells are highly susceptible to HIV-1 infection and spread.
    AIDS Res Hum Retroviruses. 2017 May 9. doi: 10.1089/AID.2017.0004.
    PubMed     Text format     Abstract available

  16. PINTO A, Carrera A, Salem H, Thapa K, et al
    Evolution of HIV-1 surveillance drug resistance mutations over ten years in New South Wales, Australia.
    AIDS Res Hum Retroviruses. 2017 May 5. doi: 10.1089/AID.2016.0301.
    PubMed     Text format     Abstract available


    Am J Epidemiol

  17. NZENZE SA, Madhi SA, Shiri T, Klugman KP, et al
    Imputing direct and indirect vaccine effectiveness of childhood pneumococcal conjugate vaccine against invasive disease by surveying temporal changes in nasopharyngeal pneumococcal colonization.
    Am J Epidemiol. 2017 May 6. doi: 10.1093.
    PubMed     Text format     Abstract available


    Antimicrob Agents Chemother

  18. PRESSIAT C, Amorissani-Folquet M, Yonaba C, Treluyer JM, et al
    Pharmacokinetics of Efavirenz in 2-3 years old children: a high dose of 25 mg/kg per day.
    Antimicrob Agents Chemother. 2017 May 8. pii: AAC.00297.
    PubMed     Text format     Abstract available


    Antivir Ther

  19. SHILAIH M, Angst DC, Marzel A, Bonhoeffer S, et al
    Antibacterial effects of antiretrovirals, potential implications for microbiome studies in HIV.
    Antivir Ther. 2017 May 12. doi: 10.3851/IMP3173.
    PubMed     Text format     Abstract available


    Clin Infect Dis

  20. BARDENHEIER BH, McNeil MM, Wodi AP, McNicholl J, et al
    Risk of non-targeted infectious disease hospitalizations among U.S. children following inactivated and live vaccines, 2005-2014.
    Clin Infect Dis. 2017 May 6. doi: 10.1093.
    PubMed     Text format     Abstract available

  21. SOCIAS ME, Nosova E, Kerr T, Hayashi K, et al
    Patterns of transmitted drug resistance and virological response to first-line antiretroviral treatment among HIV-positive people who use illicit drugs in a Canadian setting.
    Clin Infect Dis. 2017 May 6. doi: 10.1093.
    PubMed     Text format     Abstract available

  22. KAWKITINARONG K, Suwanpimolkul G, Kateruttanakul P, Manosuthi W, et al
    Real-Life Clinical Practice of Using the Xpert MTB/RIF Assay in Thailand.
    Clin Infect Dis. 2017;64.
    PubMed     Text format     Abstract available

  23. COLE SR, Edwards JK, Hall HI, Brookhart MA, et al
    Incident AIDS or Death After Initiation of Human Immunodeficiency Virus Treatment Regimens Including Raltegravir or Efavirenz Among Adults in the United States.
    Clin Infect Dis. 2017 May 12. doi: 10.1093.
    PubMed     Text format     Abstract available

  24. SEIFERT M, Georghiou SB, Garfein RS, Catanzaro D, et al
    Impact of fluoroquinolone use on mortality among a cohort of suspected drug-resistant tuberculosis patients.
    Clin Infect Dis. 2017 May 5. doi: 10.1093.
    PubMed     Text format     Abstract available

  25. BAZAN JA, Turner AN, Kirkcaldy RD, Retchless AC, et al
    Large Cluster of Neisseria Meningitidis Urethritis in Columbus, Ohio, 2015.
    Clin Infect Dis. 2017 May 8. doi: 10.1093.
    PubMed     Text format     Abstract available

  26. HARAUSZ EP, Leigh J, Garcia-Prats AJ, Furin J, et al
    Stability of Second-Line Tuberculosis Medications Mixed with Milk or Yogurt.
    Clin Infect Dis. 2017 May 6. doi: 10.1093.
    PubMed     Text format    

  27. WALKER NF, Wilkinson KA, Meintjes G, Tezera LB, et al
    Matrix Degradation in Human Immunodeficiency Virus Type 1-Associated Tuberculosis and Tuberculosis Immune Reconstitution Inflammatory Syndrome: A Prospective Observational Study.
    Clin Infect Dis. 2017 May 5. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Acquir Immune Defic Syndr

  28. HOSSEINIPOUR M, Nelson JAE, Trapence C, Rutstein SE, et al
    Viral Suppression and HIV Drug Resistance at 6 Months Among Women in Malawi's Option B+ Program: Results From the PURE Malawi Study.
    J Acquir Immune Defic Syndr. 2017;75 Suppl 2:S149-S155.
    PubMed     Text format     Abstract available

  29. PHIRI S, Tweya H, van Lettow M, Rosenberg NE, et al
    Impact of Facility- and Community-Based Peer Support Models on Maternal Uptake and Retention in Malawi's Option B+ HIV Prevention of Mother-to-Child Transmission Program: A 3-Arm Cluster Randomized Controlled Trial (PURE Malawi).
    J Acquir Immune Defic Syndr. 2017;75 Suppl 2:S140-S148.
    PubMed     Text format     Abstract available

  30. GUNDA A, Jousset A, Tchereni T, Joseph J, et al
    Integrating HIV and Maternal, Neonatal and Child Health Services in Rural Malawi: An Evaluation of the Implementation Processes and Challenges.
    J Acquir Immune Defic Syndr. 2017;75 Suppl 2:S132-S139.
    PubMed     Text format     Abstract available

  31. LUI G, Ma RCW, Chook P, Wong CK, et al
    Brief Report: Progression of Atherosclerosis in HIV-Infected Individuals-Prospective Data From an Asian Cohort.
    J Acquir Immune Defic Syndr. 2017;75:198-202.
    PubMed     Text format     Abstract available

  32. MWAPASA V, Joseph J, Tchereni T, Jousset A, et al
    Impact of Mother-Infant Pair Clinics and Short-Text Messaging Service (SMS) Reminders on Retention of HIV-Infected Women and HIV-Exposed Infants in eMTCT Care in Malawi: A Cluster Randomized Trial.
    J Acquir Immune Defic Syndr. 2017;75 Suppl 2:S123-S131.
    PubMed     Text format     Abstract available

  33. MYER L, Phillips TK
    Beyond "Option B+": Understanding Antiretroviral Therapy (ART) Adherence, Retention in Care and Engagement in ART Services Among Pregnant and Postpartum Women Initiating Therapy in Sub-Saharan Africa.
    J Acquir Immune Defic Syndr. 2017;75 Suppl 2:S115-S122.
    PubMed     Text format     Abstract available

  34. ROLLINS NC, Essajee SM, Bellare N, Doherty M, et al
    Improving Retention in Care Among Pregnant Women and Mothers Living With HIV: Lessons From INSPIRE and Implications for Future WHO Guidance and Monitoring.
    J Acquir Immune Defic Syndr. 2017;75 Suppl 2:S111-S114.
    PubMed     Text format     Abstract available

  35. BLAIS P, Sirivar S, Seto J
    Supporting Implementation Research to Improve Coverage and Uptake of HIV Related Interventions.
    J Acquir Immune Defic Syndr. 2017;75 Suppl 2:S109-S110.
    PubMed     Text format     Abstract available

  36. TEERAANANCHAI S, Bunupuradah T, Puthanakit T, Kerr SJ, et al
    First-Line Antiretroviral Treatment Outcomes and Durability in HIV-Infected Children Treated Through the Universal Coverage Health Program in Thailand.
    J Acquir Immune Defic Syndr. 2017;75:219-225.
    PubMed     Text format     Abstract available

  37. BEER L, Mattson CL, Bradley H, Shouse RL, et al
    Trends in ART prescription and viral suppression among HIV-positive young adults in care in the United States, 2009-2013.
    J Acquir Immune Defic Syndr. 2017 Apr 25. doi: 10.1097/QAI.0000000000001427.
    PubMed     Text format     Abstract available

  38. LUAN H, Han X, Yu X, An M, et al
    Dual infection contributes to rapid disease progression in men who have sex with men in China.
    J Acquir Immune Defic Syndr. 2017 May 2. doi: 10.1097/QAI.0000000000001420.
    PubMed     Text format     Abstract available

  39. CRESSEY TR, Punyawudho B, Le Coeur S, Jourdain G, et al
    Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates.
    J Acquir Immune Defic Syndr. 2017 May 9. doi: 10.1097/QAI.0000000000001447.
    PubMed     Text format     Abstract available

  40. YEN YF, Jen IA, Chen M, Lan YC, et al
    Human Immunodeficiency Virus Infection Increases the Risk of Incident Psoriasis: A Nationwide Population-based Cohort Study in Taiwan.
    J Acquir Immune Defic Syndr. 2017 Apr 25. doi: 10.1097/QAI.0000000000001431.
    PubMed     Text format     Abstract available

  41. LIU T, Hogan JW, Daniels MJ, Coetzer M, et al
    Improved HIV-1 Viral Load Monitoring Capacity using Pooled Testing with Marker-Assisted Deconvolution.
    J Acquir Immune Defic Syndr. 2017 Apr 25. doi: 10.1097/QAI.0000000000001424.
    PubMed     Text format     Abstract available

  42. VUJKOVIC M, Bellamy SL, Zuppa AF, Gastonguay M, et al
    CYP2B6 516G>T Minor Allele Protective of Late Virologic Failure in Efavirenz-treated HIV-Infected Patients in Botswana.
    J Acquir Immune Defic Syndr. 2017 May 5. doi: 10.1097/QAI.0000000000001442.
    PubMed     Text format     Abstract available

  43. KASAIE P, Pennington J, Shah MS, Berry SA, et al
    The Impact of Preexposure Prophylaxis Among Men Who Have Sex With Men: An Individual-Based Model.
    J Acquir Immune Defic Syndr. 2017;75:175-183.
    PubMed     Text format     Abstract available

  44. CHEN YH, McFarland W, Raymond HF, Scott HM, et al
    Distribution of behavioral patterns prior to infection among San Francisco men who have sex with men newly infected with HIV in 2014.
    J Acquir Immune Defic Syndr. 2017 May 5. doi: 10.1097/QAI.0000000000001439.
    PubMed     Text format     Abstract available

  45. MALEE KM, Chernoff MC, Sirois PA, Williams PL, et al
    Impact of Perinatally Acquired HIV Disease Upon Longitudinal Changes in Memory and Executive Functioning.
    J Acquir Immune Defic Syndr. 2017 May 5. doi: 10.1097/QAI.0000000000001441.
    PubMed     Text format     Abstract available

  46. OYELEDUN B, Phillips A, Oronsaye F, Alo OD, et al
    The Effect of a Continuous Quality Improvement Intervention on Retention-In-Care at 6 Months Postpartum in a PMTCT Program in Northern Nigeria: Results of a Cluster Randomized Controlled Study.
    J Acquir Immune Defic Syndr. 2017;75 Suppl 2:S156-S164.
    PubMed     Text format     Abstract available

  47. OSIBO B, Oronsaye F, Alo OD, Phillips A, et al
    Using Small Tests of Change to Improve PMTCT Services in Northern Nigeria: Experiences From Implementation of a Continuous Quality Improvement and Breakthrough Series Program.
    J Acquir Immune Defic Syndr. 2017;75 Suppl 2:S165-S172.
    PubMed     Text format     Abstract available

  48. NEWMAN OWIREDU M, Bellare NB, Chakanyuka Musanhu CC, Oyelade TA, et al
    Building Health System Capacity Through Implementation Research: Experience of INSPIRE-A Multi-country PMTCT Implementation Research Project.
    J Acquir Immune Defic Syndr. 2017;75 Suppl 2:S240-S247.
    PubMed     Text format     Abstract available

  49. MCCARTHY E, Joseph J, Foster G, Mangwiro AZ, et al
    Modeling the Impact of Retention Interventions on Mother-to-Child Transmission of HIV: Results From INSPIRE Studies in Malawi, Nigeria, and Zimbabwe.
    J Acquir Immune Defic Syndr. 2017;75 Suppl 2:S233-S239.
    PubMed     Text format     Abstract available

  50. CATALDO F, Sam-Agudu NA, Phiri S, Shumba B, et al
    The Roles of Expert Mothers Engaged in Prevention of Mother-to-Child Transmission (PMTCT) Programs: A Commentary on the INSPIRE Studies in Malawi, Nigeria, and Zimbabwe.
    J Acquir Immune Defic Syndr. 2017;75 Suppl 2:S224-S232.
    PubMed     Text format     Abstract available

  51. ORNE-GLIEMANN J, Font H, Maphosa T, Kangwende A, et al
    Patterns of Attendance at Mother Support Groups in Zimbabwe. The EPAZ Trial (2014-2016).
    J Acquir Immune Defic Syndr. 2017;75 Suppl 2:S216-S223.
    PubMed     Text format     Abstract available

  52. FOSTER G, Orne-Gliemann J, Font H, Kangwende A, et al
    Impact of Facility-Based Mother Support Groups on Retention in Care and PMTCT Outcomes in Rural Zimbabwe: The EPAZ Cluster-Randomized Controlled Trial.
    J Acquir Immune Defic Syndr. 2017;75 Suppl 2:S207-S215.
    PubMed     Text format     Abstract available

  53. ERLWANGER AS, Joseph J, Gotora T, Muzunze B, et al
    Patterns of HIV Care Clinic Attendance and Adherence to Antiretroviral Therapy Among Pregnant and Breastfeeding Women Living With HIV in the Context of Option B+ in Zimbabwe.
    J Acquir Immune Defic Syndr. 2017;75 Suppl 2:S198-S206.
    PubMed     Text format     Abstract available

  54. JOSEPH J, Gotora T, Erlwanger AS, Mushavi A, et al
    Impact of Point-of-Care CD4 Testing on Retention in Care Among HIV-Positive Pregnant and Breastfeeding Women in the Context of Option B+ in Zimbabwe: A Cluster Randomized Controlled Trial.
    J Acquir Immune Defic Syndr. 2017;75 Suppl 2:S190-S197.
    PubMed     Text format     Abstract available

  55. SAM-AGUDU NA, Ramadhani HO, Isah C, Erekaha S, et al
    The Impact of Structured Mentor Mother Programs on Presentation for Early Infant Diagnosis Testing in Rural North-Central Nigeria: A Prospective Paired Cohort Study.
    J Acquir Immune Defic Syndr. 2017;75 Suppl 2:S182-S189.
    PubMed     Text format     Abstract available

  56. SAM-AGUDU NA, Ramadhani HO, Isah C, Anaba U, et al
    The Impact of Structured Mentor Mother Programs on 6-Month Postpartum Retention and Viral Suppression among HIV-Positive Women in Rural Nigeria: A Prospective Paired Cohort Study.
    J Acquir Immune Defic Syndr. 2017;75 Suppl 2:S173-S181.
    PubMed     Text format     Abstract available


    J Infect Dis

  57. LUO Z, Li Z, Martin L, Wan Z, et al
    Pathological role of anti-CD4 antibodies in HIV-infected immunologic non-responders under viral suppressive antiretroviral therapy.
    J Infect Dis. 2017 May 11. doi: 10.1093.
    PubMed     Text format     Abstract available

  58. KEATING SM, Pilcher CD, Jain V, Lebedeva M, et al
    HIV Antibodies Detect HIV Persistence and Low Level Viral Replication.
    J Infect Dis. 2017 May 11. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Virol

  59. SHEN X, Bogers WM, Yates NL, Ferrari G, et al
    Crosslinking of a CD4 Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques.
    J Virol. 2017 May 10. pii: JVI.00401-17. doi: 10.1128/JVI.00401.
    PubMed     Text format     Abstract available

  60. JOHNSON J, Zhai Y, Salimi H, Espy N, et al
    Induction of a Tier-1-like Phenotype in Diverse Tier-2 Isolates by Agents that Guide HIV-1 Env to Perturbation-sensitive, Non-native States.
    J Virol. 2017 May 10. pii: JVI.00174-17. doi: 10.1128/JVI.00174.
    PubMed     Text format     Abstract available

  61. DECALF J, Desdouits M, Rodrigues V, Gobert FX, et al
    Sensing of HIV-1 entry triggers a type I interferon response in human primary macrophages.
    J Virol. 2017 May 10. pii: JVI.00147-17. doi: 10.1128/JVI.00147.
    PubMed     Text format     Abstract available


    Lancet Glob Health

  62. JAQUET A, Dabis F
    Smoking status and HIV in low-income and middle-income countries.
    Lancet Glob Health. 2017;5:e557-e558.
    PubMed     Text format    

  63. MDEGE ND, Shah S, Ayo-Yusuf OA, Hakim J, et al
    Tobacco use among people living with HIV: analysis of data from Demographic and Health Surveys from 28 low-income and middle-income countries.
    Lancet Glob Health. 2017;5:e578-e592.
    PubMed     Text format     Abstract available


    Lancet HIV

  64. PATON NI, Kityo C, Thompson J, Nankya I, et al
    Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.
    Lancet HIV. 2017 May 8. pii: S2352-3018(17)30065.
    PubMed     Text format     Abstract available

  65. O'CONNOR J, Smith C, Lampe FC, Johnson MA, et al
    Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study.
    Lancet HIV. 2017 May 4. pii: S2352-3018(17)30053.
    PubMed     Text format     Abstract available

  66. MAARTENS G, Meintjes G
    Resistance matters in EARNEST.
    Lancet HIV. 2017 May 8. pii: S2352-3018(17)30087.
    PubMed     Text format    

  67. DHARAN NJ, Cooper DA
    Long-term durability of HIV viral load suppression.
    Lancet HIV. 2017 May 4. pii: S2352-3018(17)30063.
    PubMed     Text format    


    Lancet Infect Dis

  68. LOBUE PA, Mermin JH
    Latent tuberculosis infection: the final frontier of tuberculosis elimination in the USA.
    Lancet Infect Dis. 2017 May 8. pii: S1473-3099(17)30248.
    PubMed     Text format     Abstract available

  69. RAJASINGHAM R, Smith RM, Park BJ, Jarvis JN, et al
    Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis.
    Lancet Infect Dis. 2017 May 5. pii: S1473-3099(17)30243.
    PubMed     Text format     Abstract available

  70. GROOME MJ, Koen A, Fix A, Page N, et al
    Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial.
    Lancet Infect Dis. 2017 May 5. pii: S1473-3099(17)30242.
    PubMed     Text format     Abstract available


    MMWR Morb Mortal Wkly Rep

  71. CAMPBELL CA, Canary L, Smith N, Teshale E, et al
    State HCV Incidence and Policies Related to HCV Preventive and Treatment Services for Persons Who Inject Drugs - United States, 2015-2016.
    MMWR Morb Mortal Wkly Rep. 2017;66:465-469.
    PubMed     Text format     Abstract available


    Nat Med

  72. STEVENSON M
    HIV persistence in macrophages.
    Nat Med. 2017;23:538-539.
    PubMed     Text format    


    Pediatr Infect Dis J

  73. NAIK NM, Mbwanji RN, Mgawe M, Ongoa R, et al
    Pharmaceutical Dosing Errors at a Pediatric HIV Clinic in Mwanza, Tanzania.
    Pediatr Infect Dis J. 2017 May 11. doi: 10.1097/INF.0000000000001639.
    PubMed     Text format     Abstract available

  74. GONDRIE IPE, Bastiaans DET, Fraaij PLA, Driessen GJA, et al
    Sustained Viral Suppression in HIV-Infected Children on Once-Daily Lopinavir/ritonavir in Clinical Practice.
    Pediatr Infect Dis J. 2017 May 4. doi: 10.1097/INF.0000000000001627.
    PubMed     Text format     Abstract available


    PLoS One

  75. CASTLEY A, Sawleshwarkar S, Varma R, Herring B, et al
    A national study of the molecular epidemiology of HIV-1 in Australia 2005-2012.
    PLoS One. 2017;12:e0170601.
    PubMed     Text format     Abstract available

  76. CURRIER JS, Britto P, Hoffman RM, Brummel S, et al
    Randomized trial of stopping or continuing ART among postpartum women with pre-ART CD4 >/= 400 cells/mm3.
    PLoS One. 2017;12:e0176009.
    PubMed     Text format     Abstract available

  77. MCCOY SI, Fahey C, Rao A, Kapologwe N, et al
    Pilot study of a multi-pronged intervention using social norms and priming to improve adherence to antiretroviral therapy and retention in care among adults living with HIV in Tanzania.
    PLoS One. 2017;12:e0177394.
    PubMed     Text format     Abstract available

  78. SOME EN, Engebretsen IMS, Nagot N, Meda NY, et al
    Changes in body mass index and hemoglobin concentration in breastfeeding women living with HIV with a CD4 count over 350: Results from 4 African countries (The ANRS 12174 trial).
    PLoS One. 2017;12:e0177259.
    PubMed     Text format     Abstract available

  79. MORA DJ, Ferreira-Paim K, Andrade-Silva LE, Bragine T, et al
    Cytokine patterns in a prospective cohort of HIV-infected patients with cryptococcal meningitis following initiation of antifungal and antiretroviral therapy.
    PLoS One. 2017;12:e0176304.
    PubMed     Text format     Abstract available

  80. PALUMBO PJ, Wilson EA, Piwowar-Manning E, McCauley M, et al
    Association of HIV diversity and virologic outcomes in early antiretroviral treatment: HPTN 052.
    PLoS One. 2017;12:e0177281.
    PubMed     Text format     Abstract available

  81. WASITTHANKASEM R, Vichaiwattana P, Siripon N, Posuwan N, et al
    Assessment of hepatitis C virus infection in two adjacent Thai provinces with drastically different seroprevalence.
    PLoS One. 2017;12:e0177022.
    PubMed     Text format     Abstract available

  82. GILBERT PB, Excler JL, Tomaras GD, Carpp LN, et al
    Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women.
    PLoS One. 2017;12:e0176428.
    PubMed     Text format     Abstract available

  83. GUTIERREZ J, Albuquerque ALA, Falzon L
    HIV infection as vascular risk: A systematic review of the literature and meta-analysis.
    PLoS One. 2017;12:e0176686.
    PubMed     Text format     Abstract available

  84. HAERI MAZANDERANI A, Moyo F, Sherman GG
    Missed diagnostic opportunities within South Africa's early infant diagnosis program, 2010-2015.
    PLoS One. 2017;12:e0177173.
    PubMed     Text format     Abstract available

  85. BIRGER RB, Le T, Kouyos RD, Grenfell BT, et al
    The impact of HCV therapy in a high HIV-HCV prevalence population: A modeling study on people who inject drugs in Ho Chi Minh City, Vietnam.
    PLoS One. 2017;12:e0177195.
    PubMed     Text format     Abstract available

  86. SEPULVEDA-TORRES LDC, Rishishwar L, Rogers ML, Rios-Olivares E, et al
    A decade of viral mutations and associated drug resistance in a population of HIV-1+ Puerto Ricans: 2002-2011.
    PLoS One. 2017;12:e0177452.
    PubMed     Text format     Abstract available

  87. MAFFIOLI EM
    Is traditional male circumcision effective as an HIV prevention strategy? Evidence from Lesotho.
    PLoS One. 2017;12:e0177076.
    PubMed     Text format     Abstract available

  88. VON REYN CF, Lahey T, Arbeit RD, Landry B, et al
    Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901.
    PLoS One. 2017;12:e0175215.
    PubMed     Text format     Abstract available


    PLoS Pathog

  89. SUI Y, Frey B, Wang Y, Billeskov R, et al
    Paradoxical myeloid-derived suppressor cell reduction in the bone marrow of SIV chronically infected macaques.
    PLoS Pathog. 2017;13:e1006395.
    PubMed     Text format     Abstract available

  90. NAKANO Y, Misawa N, Juarez-Fernandez G, Moriwaki M, et al
    HIV-1 competition experiments in humanized mice show that APOBEC3H imposes selective pressure and promotes virus adaptation.
    PLoS Pathog. 2017;13:e1006348.
    PubMed     Text format     Abstract available


    Science

  91. COHEN J
    Pinpointing HIV spread in Africa poses risks.
    Science. 2017;356:568-569.
    PubMed     Text format    


    Vaccine

  92. VIRNIK K, Nesti E, Dail C, Hockenbury M, et al
    Expression of complete SIV p27 Gag and HIV gp120 engineered outer domains targeted by broadly neutralizing antibodies in live rubella vectors.
    Vaccine. 2017 May 5. pii: S0264-410X(17)30539.
    PubMed     Text format     Abstract available

  93. BOGGIANO C, Eichelberg K, Ramachandra L, Shea J, et al
    "The Impact of Mycobacterium tuberculosis Immune Evasion on Protective Immunity: Implications for TB Vaccine Design" - Meeting report.
    Vaccine. 2017 May 2. pii: S0264-410X(17)30467.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO HIV Infection is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: